PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade

Br J Cancer. 2019 Jan;120(1):3-5. doi: 10.1038/s41416-018-0294-4. Epub 2018 Nov 9.

Abstract

Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers ('PD-Lomas') is driving the clinical research strategies for the next generation of combination immunotherapy.

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use
  • B7-H1 Antigen / antagonists & inhibitors
  • B7-H1 Antigen / immunology*
  • Clinical Trials as Topic
  • Humans
  • Immunotherapy*
  • Neoplasms / classification
  • Neoplasms / genetics
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor / immunology*
  • Signal Transduction

Substances

  • Antibodies, Monoclonal
  • B7-H1 Antigen
  • CD274 protein, human
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor